Sector News

Valeant said to step up talks on potential $800M deal for Egypt’s Amoun

June 18, 2015
Life sciences
Last month, reports said Valeant was eyeing up one of Egypt’s largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
 
The serial buyer is in advanced negotiations to buy Amoun Pharmaceutical, Bloomberg reports, though no final decision has been made–meaning any deal could still fall apart. A sale could value the company between $700 million and $800 million, the news service’s sources said in May.
 
If Valeant were to grab Amoun, it would mark its third buyout of the year. After losing out on a months-long hostile takeover try for Allergan last November, the avid dealmaker has already snapped up North Carolina’s Salix–beating out rival bidder Endo–and the assets from bankrupt Seattle biotech Dendreon in the first half of 2015.
 
But unlike those transactions–which helped the company bulk up in GI and oncology, respectively–an Amoun tie-up would strengthen Valeant in fast-growing emerging markets. Beefing up in developing nations was one perk of the proposed Allergan merger, and a goal Pearson has already worked toward with deals like 2012’s for Mexican branded-generics company Atlantis Pharma.
 
It’s all part of Valeant’s strategy to expand through M&A in high-growth spaces–both geographic and therapeutic. Before the Salix and Dendreon deals, Valeant’s moves–like the Allergan play, and its 2013 pickup of Bausch + Lomb–were centered on skincare and eye care, two other hot fields Pearson had tabbed for expansion.
 
By Carly Helfand
 

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend